Drug delivery devices and methods for drug delivery

Patent metadata

Field	Value
Publication number	US-12090292-B2
Application number	US-202117331028-A
Country	US
Kind code	B2
Filing date	May 26, 2021
Priority date	Feb 1, 2017
Publication date	Sep 17, 2024
Grant date	Sep 17, 2024

Abstract

Drug delivery devices and methods of administering drugs to patients are provided. A device includes a reservoir containing a drug. The reservoir is defined by a wall having a water-permeable portion, such that the water-permeable portion permits water to enter the device and contact the drug. A restraining plug closes off an opening of the device such that transient microchannels form between an elastic portion of the device and the restraining plug, upon the generation of a sufficient pressure within the reservoir, to release the drug from the device. Methods of treating patients for neurogenic detrusor overactivity resulting from a spinal cord injury and/or for idiopathic overactive bladder and urinary incontinence are also provided.

First claim

What is claimed is:

1. A method of treating a patient in need of treatment for neurogenic detrusor overactivity (NDO) resulting from a spinal cord injury (SCI), the method comprising:
locally administering an effective amount of trospium into the urinary bladder of the patient continuously over a treatment period of 30 to 60 days,
wherein prior to the local administering, the patient has a diagnosis of traumatic or nontraumatic suprasacral spinal cord injury for longer than 6 months and a documented history of NDO, and
wherein the locally administering an effective amount of trospium comprises releasing the trospium into urine in the bladder from a drug delivery device located within the patient's bladder, wherein the drug delivery device comprises:
a body that comprises a wall bounding a reservoir defined within the body, the wall having at least one preformed through-hole disposed therein and comprising a water-permeable portion, the body comprising an elastic portion,
a drug formulation, which comprises the trospium, disposed within the reservoir, and
a restraining plug closing off an opening of the body and contacting the elastic portion of the body, the opening being in fluid communication with the reservoir, and
wherein water diffuses through the water-permeable portion of the wall into the reservoir to contact the drug formulation to develop a hydrostatic pressure in the reservoir effective to cause the trospium to flow from the reservoir and out of the device and into the patient's bladder, and
wherein release of the trospium from the device is controlled by (i) release of the trospium through the at least one preformed through-hole in the wall, and (ii) release of the trospium through the transient formation of one or more microchannels between the elastic portion of the body and the restraining plug along an inner surface of the elastic portion of the body, extending to the opening, wherein the one or more microchannels are configured to collapse at least partially as the hydrostatic pressure is relieved.

2. The method of claim 1 , wherein the treatment period is 42 days.

3. The method of claim 1 , wherein the trospium is released into the bladder at a daily average rate of from about 2 mg/day to about 30 mg/day over the treatment period.

4. The method of claim 1 , wherein the trospium is released into the bladder at a daily average rate of from about 5 mg/day to about 25 mg/day over the treatment period.

5. The method of claim 1 , wherein the trospium is released into the bladder at a daily average rate of from about 5 mg/day to about 15 mg/day over the treatment period.

6. The method of claim 1 , wherein the trospium is released into the bladder at a daily average rate of about 10 mg/day over the treatment period.

7. A method of treating a patient in need of treatment for idiopathic overactive bladder (iOAB) and urinary incontinence, the method comprising:
locally administering an effective amount of trospium into the urinary bladder of the patient continuously over a treatment period of 30 to 60 days,
wherein prior to the local administering, the patient is diagnosed to have symptoms of OAB with urge urinary incontinence or mixed urinary incontinence with a predominant urge component for at least 6 months,
wherein the locally administering an effective amount of trospium comprises releasing the trospium into urine in the bladder from a drug delivery device located within the patient's bladder, wherein the drug delivery device comprises:
a body that comprises a wall bounding a reservoir defined within the body, the wall having at least one preformed through-hole disposed therein and comprising a water-permeable portion, the body comprising an elastic portion,
a drug formulation, which comprises the trospium, disposed within the reservoir, and
a restraining plug closing off an opening of the body and contacting the elastic portion of the body, the opening being in fluid communication with the reservoir, and
wherein water diffuses through the water-permeable portion of the wall into the reservoir to contact the drug formulation to develop a hydrostatic pressure in the reservoir effective to cause the trospium to flow from the reservoir and out of the device and into the patient's bladder, and
wherein the restraining plug controls release of the trospium from the device, via the at least one preformed through-hole, by the transient formation of one or more microchannels between the elastic portion of the body and the restraining plug along an inner surface of the elastic portion of the body, extending to the at least one preformed through-hole, upon the generation of the hydrostatic pressure, wherein the one or more microchannels are configured to collapse at least partially as the hydrostatic pressure is relieved.

8. The method of claim 7 , wherein the treatment period is 42 days.

9. The method of claim 7 , wherein the trospium is released into the bladder at a daily average rate of from about 2 mg/day to about 30 mg/day over the treatment period.

10. The method of claim 7 , wherein the trospium is released into the bladder at a daily average rate of from about 5 mg/day to about 25 mg/day over the treatment period.

11. The method of claim 7 , wherein the trospium is released into the bladder at a daily average rate of from about 5 mg/day to about 15 mg/day over the treatment period.

12. The method of claim 7 , wherein the trospium is released into the bladder at a daily average rate of about 10 mg/day over the treatment period.

Assignees

• Taris Biomedical Llc

Inventors

• Lee Heejin
• Abbate Emily
• Hocking Sarah
• Giesing Dennis

Classifications

• A61K9/0034

  Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants · CPC title

• A61M2205/0216

  Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking · CPC title

• A61M37/0069

  Devices for implanting pellets, e.g. markers or solid medicaments (for introducing of radioactive sources for interstitial radiation therapy, i.e. brachytherapy A61N5/1027) · CPC title

• A61M2205/04

  implanted · CPC title

• A61K9/0004

  Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas · CPC title